GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

HAE · Mar 29, 2025

HAEMONETICS CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000313143-25-000025General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

91.57% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.89% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

13.35% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

3.95% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

26.83% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

55.04% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

16.30% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

4.61% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2.18% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building
Mar 30, 20240/8 normalizedLevel 3Jun 29, 20240/8 normalizedLevel 3Sep 28, 20240/8 normalizedLevel 3Dec 28, 20240/8 normalizedLevel 3Mar 29, 20250/9 normalizedLevel 3Jun 28, 20250/9 normalizedLevel 3Sep 27, 20250/9 normalizedLevel 3Dec 27, 20250/9 normalizedLevel 3Mar 28, 20268/9 normalizedLevel 3Jun 27, 20268/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
351.42%
Current
91.57%
Delta
-259.85%
Capex Intensity Increased
Previous
2.45%
Current
2.89%
Delta
0.43%
Cash Generation Increased
Previous
12.56%
Current
13.35%
Delta
0.80%
Inventory Pressure Decreased
Previous
103.18%
Current
26.83%
Delta
-76.34%
Margin Decreased
Previous
55.53%
Current
55.04%
Delta
-0.49%
Profitability Decreased
Previous
16.94%
Current
16.30%
Delta
-0.64%
R And D Intensity Increased
Previous
4.54%
Current
4.61%
Delta
0.07%
Sbc Intensity Decreased
Previous
2.36%
Current
2.18%
Delta
-0.18%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · HAE Fundamental State →Has State · HAEMONETICS CORP →Transitioned To · HAE Fundamental State →Transitioned To · HAE BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · HAE CAPEX_INTENSITY_INCREASED →Transitioned To · HAE CASH_GENERATION_INCREASED →Transitioned To · HAE INVENTORY_PRESSURE_DECREASED →Transitioned To · HAE MARGIN_DECREASED →Transitioned To · HAE PROFITABILITY_DECREASED →Transitioned To · HAE R_AND_D_INTENSITY_INCREASED →Transitioned To · HAE SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.